1. The protease inhibitor E64d might attenuate the development of experimental anti-glomerular basement membrane disease through regulating the activation of Th1 cells.
- Author
-
Gu QH, Xu H, Cao X, Cheng X, Jia JY, and Yan TK
- Subjects
- Rats, Animals, Th1 Cells pathology, CD8-Positive T-Lymphocytes, Autoantigens, Cathepsins, Basement Membrane pathology, Anti-Glomerular Basement Membrane Disease drug therapy, Anti-Glomerular Basement Membrane Disease pathology, Leucine analogs & derivatives
- Abstract
Background: Cathepsins have been recently identified as a regulator in the activation of Th1 and Th17 cells, which play an important role in the pathogenesis of anti-glomerular basement membrane (GBM) disease. Whether cathepsins contribute to the development of anti-GBM disease through regulating the activation of CD4
+ T cell is still unclear., Methods: Rats with experimental anti-GBM disease was established by immunization with the nephritogenic T cell epitope α3127-148 . E64d, a cysteine cathepsin inhibitor, was administered in vitro and vivo to evaluate the effect of cathepsins on regulating the activation of antigen specific T cells and the development of anti-GBM disease., Results: In rats with experimental anti-GBM diseases, E64d treatment not only reduced the levels of proteinuria, serum creatinine and anti-GBM antibody, but also ameliorated the kidney injury with less glomerular IgG deposition, a lower percentage of crescents and less infiltration of CD4+ T cells, CD8+ T cells and macrophages, as well as a lower percentage of splenic Th1 cells. In vitro, E64d treatment could significantly reduce the production of IFN-γ in the supernatant which might be produced by the activation of Th1 cells after being recalled with the autoantigen α3127-148 . We also found the CD4+ T cells of rats with anti-GBM disease had an increased expression of cathepsin L (Cts-L), and the percentage of CD4+ T cells with extracellular expression of Cts-L was obviously higher, indicating it as a potential key regulator., Conclusions: E64d might attenuate the development of anti-GBM disease by participating in the activation of Th1 cells, indicating it as a potential drug for anti-GBM disease in the future., Competing Interests: Conflict of interest statement All the authors declared no competing interests., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF